Laddar populära aktier...
Redeye takes a more positive stance on Teneo AI following the Q3 report showing accelerating SaaS AR...
Redeye sees that the Q3 financials were not too far from our estimates (though we were slightly too ...
Redeye comments on Polygiene Group´s third quarter of the year.
Redeye sees another quarter in which BONESUPPORT delivers well on sales (beating our US CERAMENT G s...
Redeye comments on Evolution’s Q3-results which was close to our estimates and the company looks to ...
Redeye comments on SHH´s third quarter of the year.
Sales +4% vs. cons, adj. EBITA +20% vs. cons Minor positive consensus estimate revisions Awaiting im...
Redeye will likely increase its forecasts and Base Case following a solid Q3 report from Addnode.
Redeye initiates coverage of Neola Medical, a Swedish medtech company specialising in neonatal inten...
Redeye sees high uncertainty until the underlying market recovers.
Limited estimate revisions Growth appears more capital-light than history suggests Trading at '25e E...
Catalyst to grow 94% in Q3'24e EBIT revised down by 1.
Sales -8% vs. ABGSCe (-11% y-o-y), adj. EBIT -7% vs.
Redeye provides a note about CLS’s decision to concentrate fully on its neurosurgery business.
Q3 with healthy 7% organic growth despite headwinds Growth and cost improvement yields 300bp margin ...
